Synopsis
0
CEP/COS
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Solubilizers
API Stability Enhancers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
36
PharmaCompass offers a list of Bepotastine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Bepotastine manufacturer or Bepotastine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bepotastine manufacturer or Bepotastine supplier.
A Bepotastine Beslilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bepotastine Beslilate, including repackagers and relabelers. The FDA regulates Bepotastine Beslilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bepotastine Beslilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Bepotastine Beslilate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Bepotastine Beslilate supplier is an individual or a company that provides Bepotastine Beslilate active pharmaceutical ingredient (API) or Bepotastine Beslilate finished formulations upon request. The Bepotastine Beslilate suppliers may include Bepotastine Beslilate API manufacturers, exporters, distributors and traders.
click here to find a list of Bepotastine Beslilate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Bepotastine Beslilate DMF (Drug Master File) is a document detailing the whole manufacturing process of Bepotastine Beslilate active pharmaceutical ingredient (API) in detail. Different forms of Bepotastine Beslilate DMFs exist exist since differing nations have different regulations, such as Bepotastine Beslilate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Bepotastine Beslilate DMF submitted to regulatory agencies in the US is known as a USDMF. Bepotastine Beslilate USDMF includes data on Bepotastine Beslilate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Bepotastine Beslilate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Bepotastine Beslilate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Bepotastine Beslilate Drug Master File in Japan (Bepotastine Beslilate JDMF) empowers Bepotastine Beslilate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Bepotastine Beslilate JDMF during the approval evaluation for pharmaceutical products. At the time of Bepotastine Beslilate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Bepotastine Beslilate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Bepotastine Beslilate Drug Master File in Korea (Bepotastine Beslilate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Bepotastine Beslilate. The MFDS reviews the Bepotastine Beslilate KDMF as part of the drug registration process and uses the information provided in the Bepotastine Beslilate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Bepotastine Beslilate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Bepotastine Beslilate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Bepotastine Beslilate suppliers with KDMF on PharmaCompass.
A Bepotastine Beslilate written confirmation (Bepotastine Beslilate WC) is an official document issued by a regulatory agency to a Bepotastine Beslilate manufacturer, verifying that the manufacturing facility of a Bepotastine Beslilate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Bepotastine Beslilate APIs or Bepotastine Beslilate finished pharmaceutical products to another nation, regulatory agencies frequently require a Bepotastine Beslilate WC (written confirmation) as part of the regulatory process.
click here to find a list of Bepotastine Beslilate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bepotastine Beslilate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bepotastine Beslilate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bepotastine Beslilate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bepotastine Beslilate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bepotastine Beslilate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bepotastine Beslilate suppliers with NDC on PharmaCompass.
Bepotastine Beslilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bepotastine Beslilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Bepotastine Beslilate GMP manufacturer or Bepotastine Beslilate GMP API supplier for your needs.
A Bepotastine Beslilate CoA (Certificate of Analysis) is a formal document that attests to Bepotastine Beslilate's compliance with Bepotastine Beslilate specifications and serves as a tool for batch-level quality control.
Bepotastine Beslilate CoA mostly includes findings from lab analyses of a specific batch. For each Bepotastine Beslilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bepotastine Beslilate may be tested according to a variety of international standards, such as European Pharmacopoeia (Bepotastine Beslilate EP), Bepotastine Beslilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bepotastine Beslilate USP).
